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TO THE EDITOR
Pemphigus is a rare autoimmune
blistering disease characterized by high
levels of antibodies against the epider-
mal attachment components, desmo-
glein1 (Dsg-1) and desmoglein3 (Dsg-3;
Amagai, 1999). Intravenous Ig (IVIg)
reduces the levels of these antibodies,
as well as clinical manifestations of
pemphigus, but its mechanism of action
is unknown (Czernik et al., 2008).
There is emerging evidence that pem-
phigus antibodies can cause keratino-
cyte apoptosis and contribute to
acantholysis (Arredondo et al., 2005; Li
et al., 2009; Schmidt and Waschke,
2009). Inhibitors of apoptotic proteins
(IAPs) can target the caspases, and
increases in their levels lead to resistance
to apoptosis (Schimmer, 2004). Antia-
poptotic effect of IVIg on keratinocytes is
well known in disorders such as toxic
epidermal necrolysis (Viard et al., 1998).
Our goal in this study was to determine
whether IAP levels change in sera during
IVIg therapy as a possible mechanism of
suppression of acantholysis.
We measured three IAPs (survivin,
livin, and X-linked IAP (XIAP)) in sera of
seven patients with active pemphigus
(five pemphigus vulgaris and two
pemphigus foliaceus) before and after
treatment with 10% IVIg (Gamunex,
Talecris Biotherapeutics, Durham, NC).
Average age of the patients was 59
(45–74) years. Each course of IVIg
consisted of four cycles, administered
every 2 weeks. Each cycle consisted of
400 mg kg1 per day infused slowly for
5 days. In four patients, IVIg was
administered together with 50–200 mg
per day of oral cyclophosphamide.
All patients were under treatment with
prednisone (20–80 mg per day) before
IVIg therapy. Sera were collected
before treatment, 1 and 2 weeks after
the first and 1 and 4 weeks after the
fourth IVIg cycle. All patients gave
written informed consent according to
the Declaration of Helsinki Principles,
and the study was approved by the
New York University Institutional
Review Board. Serum levels of inter-
cellular IgG antibodies were measured
by indirect immunofluorescence using
esophagus of rhesus monkey as the
substrate. Skin cryosections were incu-
bated with serial serum dilutions of
1:10 to 1:1,280. Goat anti-human
IgG-FITC was used as the secondary
antibody and slides were analyzed
with an epiluminescence microscope.
Anti-Dsg-1 and anti-Dsg-3 antibodies
were measured by ELISA, using a kit
from MBL International, Woburn, MA,
and monoclonal mouse anti-human
IgG4 antibodies (GeneTex, Irvine,
CA) with the technique described
previously (Green and Bystryn, 2008).
Disease severity was measured using
a score described earlier (Lolis et al.,
2011). For quantitative measurement of
IAPs, ELISA kits from R&D Systems,
Minneapolis, MN were used according
to the manufacturer’s instructions.
Serum survivin, livin, and XIAP
were measured in 31 healthy indivi-
duals, and the average levels were
40.1 pg ml1 (SD¼±8.4), 26.2 pg ml1
(±14.4), and 0.9 mg ml1 (±0.29),
respectively. Pretreatment levels of
XIAP and livin in pemphigus patients
(Table 1) were not significantly different
from those of healthy individuals. Survivin
Abbreviations: Dsg-1, desmoglein1; IAP, inhibitors of apoptotic proteins; IVIg, intravenous Ig; XIAP,
X-linked inhibitor of apoptotic proteins
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was significantly higher in healthy
individuals (P-value¼0.03). Analyses
were performed using Student’s t-test
in Excel. One week after the first
IVIg cycle, serum levels of livin
and XIAP were markedly and signifi-
cantly increased in all patients and,
compared with the baseline, the average
levels showed 786% and 155%
increases, respectively (P-values¼0.002
and 0.039). Survivin levels remained
balanced before and after treatment,
and the difference was not statistically
significant (Table 1). Two weeks after
the first IVIg cycle, livin and XIAP levels
were still higher than the baseline, with
the greatest increase observed 1 week
after the fourth IVIg cycle. Four weeks
after the fourth IVIg cycle, livin and XIAP
levels were still 315% and 58% higher
than the baseline (Figure 1 and Table 1).
To confirm ELISA findings, western
blotting was also performed in three
patients and the results were compatible
with that of ELISA (Figure 1). In the IVIg
preparation, levels of survivin, livin, and
XIAP were 41.2, 22.3 pg ml1, and
0.59mg ml1, respectively. These values
were not significantly different from
those of healthy individuals or patients
before treatment. To evaluate the
possible effect of IVIg contained in the
test samples on IAP ELISAs, we measured
serum total IgG before and after each
IVIg cycle (Table 1). After the first cycle,
IgG concentration increased by 177%.
We concluded that a 786% increase
in livin was less likely due to the impact
of IVIg. One and four weeks after the
last IVIg cycle, these differences were
even more striking. Although changes
in XIAP were close to those of total IgG,
considering that livin and survivin
changed independent of IgG, we con-
clude that the elevation of IAPs as
analyzed by ELISA was not due to IVIg
Table 1. Changes in average disease severity score, pemphigus antibody titers, and IAPs in seven patients with
pemphigus during treatment with IVIg
Pre-Tx
1-W post 1st IVIg
cycle
2-W post 1st IVIg
cycle
1-W post 4th IVIg
cycle
1-M post 4th IVIg
cycle
Survivin (pg ml1)±SD (D%) 30.9±8.18 33.6±6.4 (8) 30.4±5.3 (1.8) 29.6±4.8 (4) 29.3±5.1 (5)
Livin (pg ml1)±SD (D%) 15.7±12.08 139.4±18.7 (786) 86.7±16.4 (451) 240±21.4 (1427) 65.3±14.4 (315)
XIAP (mg ml1)±SD (D%) 0.9±0.46 2.2±0.62 (155) 1.5±0.37 (78) 3.1±0.51 (268) 1.3±0.5 (58)
DSS±SD (D%) 11±2.2 9.7±3.1 (11) 9±3.7 (18) 8±3.7 (27) 9±3.1 (18)
IIF IgG±SD (D%) 248.6±32.2 180±21.4 (27) 77.1±19.3 (69) 100±22.8 (59) 72.9±23.9 (70)
Anti-Dsg-1 or -Dsg-3 IgG4 (U ml1)±SD
(D%)
40.2±14.2 34±14.2 (15) 28.9±11.1 (28) 11.8±7.4 (70) 22.9±12.2 (43)
Total IgG (g l1)±SD (D%) 11.2±4.2 31.1±5.6 (177) 23.2±4.4 (107) 54.4±11.3 (385) 19.2±4.4 (71)
Abbreviations: Dsg, desmoglein; DSS, disease severity score; IAP, inhibitors of apoptotic protein; IIF, indirect immunofluorescence; IVIg, intravenous Ig;
Tx, treatment; XIAP, X-linked inhibitor of apoptotic protein.
1,000
100
10
0
–50
–100
Pre-Tx
Livin
XIAP
Survivin
39 kDa
55 kDa
17 kDa
1-W post
1st
IVI
g
Pre
-Tx
Co
ntr
ol (
–)
He
alt
hy
 co
ntr
ol
Sta
nd
ard
 (+)
4-W
 po
st 
4th
1-W
 po
st 
4th
2-W
 po
st 
1s
t
1-W
 po
st 
1s
t
2-W post
1st
1-W post
4th
4-W post
4th
IIF IgG
DSS
Survivin
XIAP
Livin
Pe
rc
en
t c
ha
ng
e
Anti-Dsg-1/3
IgG4
Figure 1. Serum levels of livin and XIAP increase during IVIg therapy for pemphigus. Changes in the
average serum levels of inhibitors of apoptotic proteins (IAPs) measured by ELISA, disease severity score,
and antibody titers in seven pemphigus patients during IVIg therapy (a), and western blot of serum IAPs in
a pemphigus patient during IVIg therapy, and a healthy individual (b). For western blotting, 20mg of
protein was loaded on 10% SDS-PAGE gel and then transferred to nitrocellulose membrane. After
blocking with 5% non-fat milk in Tris-buffered saline and 0.1% Tween 20, membranes were incubated
with primary antibodies (goat polyclonal anti-human total livin, rabbit polyclonal anti-human survivin,
and goat polyclonal anti-human XIAP, R&D Systems), followed by horseradish peroxidase-conjugated
secondary antibodies. The immunoblots were developed using the enhanced chemoluminescence
detection system. DSS, disease severity score; Dsg, desmoglein; IIF, indirect immunofluorescence; IVIg,
intravenous Ig; Tx, treatment; XIAP, X-linked inhibitor of apoptotic protein.
2328 Journal of Investigative Dermatology (2011), Volume 131
S Toosi et al.
IAPs in Sera during IVIg for Pemphigus
contained in the test sera. Nevertheless,
our findings do not allow to formally
exclude a direct impact of IVIg con-
centration on the performance of our
solid-phase assay. Furthermore, IVIg is a
heterogeneous product with various
effects and possible nonspecific bind-
ings. Disease severity scores, levels of
intercellular antibodies, and anti-Dsg-1
or -Dsg-3 IgG4 antibodies decreased
during IVIg therapy, showing both
laboratory and clinical improvement of
the disease (Table 1 and Figure 1).
Evidence for effects of disease anti-
bodies on apoptotic pathways have
been observed in pemphigus. Increased
expression of multiple caspases has
been detected in lesions of pemphigus
patients (Puviani et al., 2003; Wang
et al., 2004). In skin cultures, activation
of initiator caspases is seen after
treatment with pemphigus IgG (Arre-
dondo et al., 2005; Schmidt et al.,
2009). Furthermore, administration of
caspase inhibitors protects mice from
developing blisters induced by pemphi-
gus antibodies (Li et al., 2009),
which strongly suggests that caspase
activation is critically involved in the
formation of acantholysis. Livin and
XIAP have similar Baculoviral IAP
repeats inhibiting similar caspases and
both have a really interesting new gene
domain that has a role in protein
ubiquitination, which can induce in-
flammation and immunity. Survivin is
structurally different from other IAPs
because it lacks the really interesting
new gene domain. Survivin is known to
function as a major factor in cytokin-
esis, contributing to the resistance of
cancer cells to apoptosis (Richter and
Duckett, 2000).
In summary, we found that serum
levels of livin and XIAP increase mark-
edly with IVIg therapy, which is ac-
companied by a decrease in the levels
of pathogenic autoantibodies, as well as
disease severity. These results indicate
that increase in serum livin and XIAP
may be associated with clinical benefits
of IVIg. Although the sample size was
small, the striking results we report may
suggest performing functional studies
on the role of IAPs in the mechanism of
action of IVIg in preventing acantholy-
sis. In addition, evaluation of IAPs in
other IVIg-treated inflammatory disor-
ders is useful in further understanding
the mechanism of action of IVIg.
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TO THE EDITOR
The p16INK4a cyclin-dependent kinase
inhibitor acts as a negative regulator
of cyclin D-dependent kinases and is
a critical gatekeeper at the G1–S check-
point (Serrano et al., 1996). Accord-
ingly, p16INK4a is frequently inactivated
in human tumors, and deletions invol-
ving this locus occur frequently in
melanomas. Inherited mutations in the
p16INK4a gene are also associated with
melanoma susceptibility in 40% of multi-
ple-case melanoma families (Goldstein
et al., 2006). It is generally acknowl-
edged that the progressive and gradual
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